Your session is about to expire
← Back to Search
Antibody-drug conjugate
TR1801-ADC in Patients With Tumors That Express c-Met
Phase 1
Waitlist Available
Research Sponsored by Open Innovation Partners, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3.5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests TR1801-ADC, an experimental drug, in patients with certain solid tumors that have the c-Met marker. The drug aims to kill cancer cells by targeting the c-Met marker.
Eligible Conditions
- Unspecified Adult Solid Tumor Protocol Specific
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3.5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3.5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met
Establish maximum tolerated dose
Secondary study objectives
Evaluate clinical activity of TR1801-ADC
Evaluate pharmacokinetics of TR1801-ADC
Immunogenicity
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TR1801-ADCExperimental Treatment1 Intervention
Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
Find a Location
Who is running the clinical trial?
Open Innovation Partners, Inc.Lead Sponsor
Tanabe Research Laboratories USA IncLead Sponsor
Open Innovation PartnersUNKNOWN
Ken Carlson, MDStudy DirectorTanabe Research Laboratories
Rita Laeufle, MD, PhDStudy DirectorTanabe Research Lab
Gilad Gordon, MDStudy DirectorOpen Innovation Partners
4 Previous Clinical Trials
296 Total Patients Enrolled